


3D genomic analysis reveals novel enhancer-hijacking caused by complex structural alterations that drive oncogene overexpression

Katelyn L. Mortenson¹, Courtney Dawes², Emily R. Wilson¹, Nathan E. Patchen², Hailey E. Johnson^{1,3}, Jason Gertz¹, Swneke D. Bailey^{4,5}, Yang Liu², Katherine E. Varley^{1,*}, Xiaoyang Zhang^{1,*}

1. Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA
 2. Department of Biochemistry, University of Utah, Salt Lake City, Utah, USA
 3. Department of Cell Biology and Physiology, Brigham Young University, Provo, Utah, USA
 4. Cancer Research Program, Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
 5. Departments of Surgery and Human Genetics, McGill University, Montreal, QC, Canada.
- *. Corresponding authors:
Katherine E. Varley (Katherine.Varley@hci.utah.edu) and Xiaoyang Zhang (Xiaoyang.Zhang@hci.utah.edu).

ABSTRACT

Enhancer hijacking, caused by structural alterations on chromosomes as well as extrachromosomal DNA (ecDNA), is a common cancer driver event. The complexity and ubiquity of structural alterations in cancer genomes make it difficult to identify enhancer hijacking using genome sequencing alone. Here we describe a 3D genomics-based analysis called HAPI (Highly Active Promoter Interactions) to characterize enhancer hijacking caused by structural alterations. HAPI analysis of HiChIP data from 34 cancer cell lines identified novel enhancer hijacking events that involve chromosomal rearrangements and activate both known and potentially novel oncogenes such as *MYC*, *CCND1*, *ETV1*, *CRKL*, and *ID4*, which we validated using CRISPRi assays and RNA-seq analysis. Furthermore, we found that ecDNAs often contain multiple oncogenes from different chromosomes, which causes nested enhancer hijacking among them. We found that ecDNAs containing *MYC* often harbor additional oncogenes from other chromosomes such as *CDX2*, *ERBB2*, or *CD44* that co-opt *MYC*'s enhancers for their overexpression, which we validated using dual-color DNA FISH and CRISPRi assays. These enhancer hijacking events involving multiple oncogenes on ecDNAs have important implications for therapeutic strategies that either target the co-opting oncogenes or the hijacked enhancers. Our publicly available HAPI analysis tool provides a robust strategy to detect enhancer hijacking and reveals novel insights into oncogene activation caused by chromosomal and extrachromosomal structural alterations.



Graphic abstract

INTRODUCTION

Somatic structural variants, including deletions, duplications, inversions, and translocations, dramatically alter genomic structures in cancer cells. These events can be readily detected by DNA imaging, whole-genome/long-read sequencing, or Hi-C-based 3D genomic assays¹⁻⁵. Understanding the functional consequences of structural variants is key to uncovering the mechanisms of tumorigenesis and developing therapeutic strategies. For instance, structural variants can create a fusion gene with oncogenic properties such as *BCR-ABL1* and *EML4-ALK*^{6,7}. However, most of the breakpoints of cancer-associated structural variants fall in noncoding regions⁸. These variants can place enhancer elements adjacent to oncogenes such as *MYC*, *MYCN*, *MYB*, *CCND1*, *EVII*, and *GFI1*, and activate their expression, events known as ‘enhancer hijacking’⁹⁻¹⁷.

Several analysis approaches have been developed to identify enhancer hijacking. PANGEA and CESAM identify candidate genes based on the correlation of their expression with adjacent structural alterations across tumor samples, which require large cohorts of data and do not utilize chromatin interaction evidence of enhancer hijacking^{18,19}. Neoloop reconstructs Hi-C maps in structurally altered cancer genomes to identify aberrant chromatin loops and their associated genes²⁰, however, it does not prioritize the gene targets and the underlying functional enhancers. As structural variants often affect many enhancer-promoter interactions, most of which are likely passenger events^{2,3}, it is essential to prioritize the functional elements. Furthermore, recent work has revealed that complex structural variants such as chromothripsis lead to the formation of circular extrachromosomal DNA (ecDNA)²¹. These events often cause extensive alterations of enhancer-promoter interactions, posing another challenge to characterize the underlying mechanisms of oncogene regulation²²⁻²⁴.

Here, we propose a 3D genomics-based strategy to identify and characterize enhancer hijacking events based on two assumptions: 1) oncogenes subject to enhancer hijacking should be highly regulated by enhancers; 2) the hijacked enhancers should contribute a substantial proportion of an oncogene’s enhancer usage. To test this, we utilized H3K27ac HiChIP data to map enhancer-promoter interactions and measured their interaction intensities. We applied our strategy to HiChIP data from 34 cancer and two normal cell lines. This approach identified known and novel enhancer hijacking events, prioritized their target genes, and defined the underlying enhancers. This approach also revealed novel enhancer hijacking mechanisms associated with ecDNAs or complex chromosomal amplicons. In these events, multiple oncogenes from different chromosomal regions are translocated near each other, copy number amplified together, and hijack each other’s enhancers to boost their overexpression.

RESULTS

HAPI analysis identifies genes that are highly interactive with enhancers.

We first developed an analysis method, Highly Active Promoter Interactions (HAPI), that utilizes H3K27ac HiChIP data to quantify all enhancer interactions of each gene’s promoter in the genome, including intra- and inter-chromosomal interactions. This method ranks genes by 1) their enhancer contact value defined as the number of interacting enhancers and 2) their interaction intensity as defined by the number of HiChIP paired-end tags (PETs). We define highly interactive (HAPI) genes as those that exceed the inflection points of both the ranked enhancer contact value and ranked interaction intensity in a manner similar to previously published methods that define super-enhancers²⁵ (Figure 1A), as exemplified in LNCaP cells (Figure 1B and S1A-B).

We applied HAPI analysis to H3K27ac HiChIP data that we and others generated in 34 cancer cell lines representing multiple cancer types (Table S1), which identified on average 584 HAPI genes in each cell line (Table S2). In the prostate cancer cell line LNCaP, HAPI genes are more likely to interact with super-enhancers compared to non-HAPI enhancer-connected genes as expected^{26,27} (Figure S1C), but there are additional highly interactive HAPI genes that do not utilize super-enhancers (Figure S1C). Overexpressed oncogenes such as *MYC*, *FOXA1*, *TBX3*, and *PCAT1* were identified as HAPI genes in LNCaP cells. Notably, HAPI genes are not necessarily genes with the highest expression, as highly expressed housekeeping genes *ACTB*, *HPRT1*, and *GAPDH* fell below the HAPI cutoff (Figure 1B and S1D). Furthermore, when we investigated whether copy number amplification had an impact HAPI gene metrics, we found that only a small proportion of the amplified genes are identified as HAPI genes, suggesting that copy number amplification does not bias the calling of HAPI

genes (Figure S1E). We did not normalize copy number variants in this analysis, as we and others have shown that focal copy number amplifications contribute to enhancer-promoter interactions for oncogenes – a signal that we want to preserve in our analysis²⁸⁻³³.

Figure 1




Figure 1: HAPI analysis identifies cancer-related genes that are highly interactive with enhancers. **A.** Schematic model illustrating the identification of HAPI genes based on enhancer interactions. **B.** Plotted are the number of enhancers (x-axis) and interaction intensity (y-axis) for each gene in LNCaP cells. HAPI cutoff is defined by the inflection point of each scoring metric. **C.** Spearman correlation clustering of cancer cell lines based on normalized interaction scores of their associated HAPI genes. **D.** The percentage of HAPI and non-HAPI genes (shared by cell lines in each indicated cluster) that are previously annotated as oncogenes. The numbers outside and within each bar indicate the total number of HAPI (red) or non-HAPI (grey) genes and the ones annotated as oncogenes, respectively. P-values are derived from Fisher's exact tests.

We performed unsupervised clustering of the cell lines based on a combination of the enhancer contact and interaction intensity values for each identified HAPI gene (Figure 1C, see Methods for more details). The results showed that cell lines from the same lineages clustered together, highlighting the cancer type-specificity of HAPI genes. We also found significant enrichments of previously annotated oncogenes³⁴⁻³⁶, and genes involved in cancer-related pathways in our identified HAPI gene lists (Figure 1D and Table S3). Overall, HAPI analysis identified known cancer-related genes that are highly interactive with enhancers in a cancer-type specific manner.

HAPI analysis identifies known and novel enhancer-hijacking events.

HAPI analysis not only defines genes that are highly interactive with enhancers but also determines the location of their enhancers. This enables us to determine whether the enhancers are in the same genomic region as the HAPI gene or are hijacked from other genomic regions likely through structural alterations (Figure 2A). These

include both ‘trans’ hijacking events that relocate enhancers from other chromosomes to a HAPI gene and ‘cis’ hijacking events that relocate distant enhancers (>2Mb, the upper limit of TAD domains³⁷) on the same chromosome.

We analyzed H3K27ac HiChIP data of the 34 cancer cell lines to determine the origin of enhancers for HAPI genes. For HAPI genes with over 25% of enhancer activity coming from either abnormal trans- or cis- interactions were treated as candidate genes driven by enhancer hijacking. In total, we identified enhancer hijacking genes in 31 of the 34 cell lines (Figure 2B). In this study, we focus on trans-enhancer hijacking events because they are more likely caused by structural alterations than cis-enhancer hijacking events that may be caused by other types alterations such as epigenetic loss of TAD boundaries^{38,39}. We found trans-enhancer hijacking events in 19 of the cancer cell lines, but in neither of the two normal cell lines we examined (Figure 2C). The calculated enhancer origins, both trans and cis, for all HAPI genes are listed in Table S2.

In addition to enhancer origins, we also examined copy numbers of the HAPI genes using published SNP-array data⁴⁰. We first focused on genes that exhibit neutral copies or modest amplifications ($\log_2(\text{CN}) < 2$) (Figure 2D-E). This analysis identified previously reported trans-enhancer hijacking events activating oncogenes *CCND1* in the B-cell lymphoma cell line REC1^{10,12} and *ETV1* in the prostate cancer cell line LNCaP^{20,41}. We also found novel trans-enhancer hijacking events activating known oncogenes including *MYC* in the small cell lung cancer cell line NCIH146, *NOTCH1* in the T-cell lymphoblastic leukemia cell line CUTLL1, *CCND1* in the breast cancer cell line ZR75, and *ETV1* in another prostate cancer cell line MDA-PCA-2B. Furthermore, HAPI analysis identified potentially novel oncogenes that hijack enhancers in trans, such as *CRKL* in the colorectal cancer cell line HT29 and *FOXJ2* in the small cell lung cancer cell line NCIH2171 (Figure 2D and S2A). Finally, we found cis-enhancer hijacking events activating potentially novel oncogenes such as *ID4* in the prostate cancer cell line VCaP and *TXLNA* in the small cell lung cancer cell line CORL88 (Figure 2E), which are likely caused by large deletions based on the known patterns of structural variants in the HiChIP signal (Figure S2B-D). Overall, cell lines with these enhancer-hijacking events are associated with higher expression of the involved genes as compared to other cell lines of the same lineage (Figure 2D-E and S2A).

Functional validation of identified enhancer hijacking events.

We then chose two representative enhancer hijacking genes identified from HAPI analysis for functional validation. We identified *ETV1* (chromosome 7) as a trans-enhancer hijacking gene in both LNCaP and MDA-PCA-2B cells, with most of its trans enhancer activity coming from chromosome 14 (Figures 3A). This is caused by a cryptic insertion in LNCaP⁴¹ and a balanced translocation in MDA-PCA-2B⁴² that connect the two chromosomal regions. Utilizing structural variants called by Pan-Cancer Analysis of Whole Genomes (PCAWG), we also identified one primary prostate cancer patient tumor sample harboring a translocation linking these two regions (Figure S3A). Previous studies have identified various potential enhancers within regions of this translocation in LNCaP, but a consensus regarding which one regulates *ETV1* has not yet been reached^{20,42}. Based on H3K27ac HiChIP and ChIP-seq signal, we observed four enhancers e1-e4, upstream of *FOXA1* on chromosome 14, hijacked to the *ETV1* promoter in LNCaP and MDA-PCA-2B cells (Figure 3A). CRISPRi assays in LNCaP showed that repression of e3 and e4 caused the most significant decreases in expression of *ETV1* (Figure 3B). H3K27ac ChIP-seq performed after CRISPRi confirmed the on-target effects of CRISPRi (Figure S3B). As a control, repression of the four enhancers did not affect *ETV1* expression in 22RV1 cells that lack the translocation (Figure S3C). Interestingly, these enhancers have minimal regulatory effects on the nearby gene *FOXA1* or *TTC6* on their original chromosome in both LNCaP and 22RV1 (Figure 3B and S3D-E), indicating that these two genes may be dependent on other enhancers.

ETV1 was reported as an androgen-responsive gene in LNCaP cells promoting cell invasion⁴³. We observed binding of androgen receptor (AR) to both e3 and e4 but not the promoter of *ETV1* (Figure 3A and S3F). Additionally, we observed a 40% upregulation of *ETV1* expression in response to Dihydrotestosterone (DHT) treatment in LNCaP cells. In contrast, *ETV1* expression is minimally affected by DHT in the untranslocated 22RV1 cells, where AR binds the e3 and e4 enhancers in their original locus (Figure S3G). These data suggest that the androgen-induced *ETV1* upregulation is caused by these two hijacked AR-bound enhancers.

Figure 2




Figure 2: HAPI analysis identifies known and novel enhancer-hijacking events. A. Schematic model illustrating the identification of enhancer hijacking HAPI genes based on the enhancer origin. **B.** The number of cell lines that are identified to contain trans- and cis-enhancer hijacking events in our cohort. **C.** The number of identified trans-enhancer hijacking events found in each cancer cell line in our cohort. Two immortalized epithelial cell lines are used as negative controls. **D.** Plotted are the calculated trans-enhancer contribution (x-axis) and the copy number estimated by SNP-array data (y-axis) for each HAPI gene in selected cell lines. The top one trans-enhancer hijacking gene is highlighted. Besides are the expression levels for the highlighted gene in all CCLE cell lines (violin plot), the trans-enhancer hijacking cell line (red), and other cell lines of the same lineage (blue). **E.** Same as D but with regards to two cis-enhancer hijacking genes in VCaP and CORL88 cells.

The second representative enhancer hijacking gene we selected from HAPI analysis for functional validation was *CCND1*. *CCND1* (chromosome 11) is known to hijack enhancers from chromosome 14 in the B-cell lymphoma cell line REC1^{10,12}. We found that the same oncogene hijacks different enhancers from chromosome 8 in the breast cancer cell line ZR751 (Figure 3C). WGS analysis revealed a translocation that places these enhancers upstream of *CCND1* in ZR751 (Figure 3C). In primary breast cancer patient tumor samples from PCAWG, although we did not observe the same translocation event, we found that the *CCND1* locus is highly subject to

Figure 3




Figure 3: Functional validation of identified trans-enhancer hijacking events. A. HiChIP and ChIP-seq signal at chromosomal regions containing *ETV1* and the hijacked enhancers in MDA-PCA-2B and LNCaP cells. WGS-identified breakpoints support translocations underlying the enhancer-hijacking events. **B.** RT-qPCR measuring expression changes of *ETV1* and *FOXA1* after CRISPRi of each enhancer e1-e4 or the promoter of *ETV1* in LNCaP cells. Expression levels were normalized to cells treated with a non-targeting sgRNA (NT1). N = 3 biological replicates. P-values were derived from two-sided t-tests. **C.** HiChIP and ChIP-seq signal at chromosomal regions containing *CCND1* and the hijacked enhancers in REC1 and ZR751 cells. In ZR751 cells, WGS-identified breakpoints support translocations underlying the enhancer-hijacking events. **D.** RT-qPCR measuring expression changes of *CCND1* and *DUSP4* after CRISPRi of each enhancer e1-e5, the promoter of *CCND1*, or a combination using selected enhancer targeting sgRNAs (*) in ZR751 cells. Expression levels were normalized to cells treated with a non-targeting sgRNA (NT1). N = 3 biological replicates. P-values were derived from two-sided t-tests.

translocations with diverse regions of chromosome 8 (Figure S3H). We applied CRISPRi to repress six of the strongest enhancers (e1-e5 in Figure 3C) individually or simultaneously in ZR751. Targeting e3, e5, and the combination of all enhancers with CRISPRi caused a 20-50% decrease in *CCND1* expression (Figure 3D). Repression of these enhancers also caused a 20-90% decrease in expression of their endogenous target gene *DUSP4* on chromosome 8 (Figure 3D). These results together demonstrate that these enhancers activate *CCND1* due to enhancer hijacking while also acting in their canonical role of activating *DUSP4*. *CCND1* is overexpressed in 50% of breast cancers, which has been partially attributed to gene amplification⁴⁴. It is possible that enhancer hijacking may serve as an additional mechanism for *CCND1* overexpression in breast cancers.

The hijacked enhancers on chromosome 8 in ZR751 exhibit H3K27ac enrichment in the breast cancer cell line T47D without the translocation (Figure S4A), but little enrichment in B-cell lymphoma line REC1 in which *CCND1* hijacks enhancers from chromosome 14 (Figure 3C). The reciprocal pattern was observed for the enhancers hijacked in REC1 (Figure S4A). These results indicate that the enhancers involved in hijacking are already active in cancer cells without the translocation and are cancer-type specific. To support this finding, we utilized TCGA ATAC-seq data to estimate potential regulatory activity of translocated enhancer clusters we identified in breast, prostate, and colon cancers. Five of the eight examined enhancer regions have increased ATAC-seq signal in tumors of their respective cancer types compared to others (Figure S4B). These data together suggest that cancer-type specific enhancers may be subject to translocations to activate oncogene expression.

HAPI analysis identifies novel enhancer hijacking mechanism associated with ecDNAs.

Some of the identified enhancer hijacking genes exhibit high copies ($\log_2(\text{CN}) > 2$). Recent studies have revealed that oncogenes amplified in the form of ecDNAs tend to exhibit higher copies compared to their chromosomal amplifications⁴⁵. As illustrated in Figure 4A, the high copy number of ecDNAs, along with increased chromatin accessibility, results in the overexpression of oncogenes such as *EGFR* in glioblastoma⁴⁵. In addition, enhancer hijacking, as a result of complex rearrangements on ecDNAs, also contributes to oncogene expression as exemplified by *MYCN* in neuroblastoma¹⁵. In our dataset, the colorectal cancer cell line COLO320DM and the gastric adenocarcinoma cell line SNU16 are known to contain ecDNAs amplifying the *MYC* oncogene⁴⁶. HAPI analysis revealed novel enhancer hijacking events in both the cell lines, which involve multiple oncogenes on the same ecDNA.

COLO320DM contains an ecDNA harboring a *PVT1-MYC* fusion driven by the *PVT1* promoter and several other genes including *CDX2*, *PDX1*, and *DUSP22*⁴⁶. As a HAPI gene, *PVT1-MYC* has most of its enhancer activity contributed in *cis*. Interestingly, *CDX2*, a colorectal cancer lineage-survival oncogene^{47,48} from chromosome 13, is identified as a trans-enhancer hijacking HAPI gene (Figure 4B), with over 95% of enhancer activity in trans. Indeed, most of the enhancer activity for *CDX2* comes from the *MYC* locus on the ecDNA (Figures 4C-E). These results suggest two separate mechanisms through which the ecDNA causes overexpression of oncogenes in COLO320DM cells – while *MYC* uses its co-amplified endogenous enhancers, *CDX2* hijacks *MYC* enhancers on the same ecDNA to enhance its expression, representing an “opportunistic” enhancer hijacking mechanism (Figure 4D).

SNU16 contains multiple ecDNA isoforms harboring the *MYC* and *FGFR2* oncogenes separately^{46,49}. The *MYC* ecDNA harbors three other genes from chromosome 11, including *APIP*, *PDHX*, and *CD44*, which are involved in the development of gastric adenocarcinoma^{50,51}. HAPI analysis identified these three genes as enhancer hijacking genes (Figure 4F), which have 33%-42% of enhancer activity contributed from enhancers near *MYC* on chromosome 8 that are now on the same ecDNA (Figures 4G-I). Vice versa, *MYC* also has most of the enhancer activity contributed in trans from other chromosomal regions on the same ecDNA (Figure 4G-I). These reciprocal enhancer-oncogene interactions represent a “mutualistic” enhancer hijacking mechanism on ecDNAs (Figure 4H). Interestingly, although the *FGFR2* ecDNA does not include regions from other chromosomes based on previous reports⁴⁶, it has 52% of enhancer activity contributed in trans (Figure 4F-G). This is likely caused by the reported intermolecular interactions between *MYC* and *FGFR2* ecDNAs as well as the presence of chimeric *MYC-FGFR2* ecDNA in a small proportion of the ecDNAs in this cell line⁴⁶.

Figure 4




Figure 4: Novel enhancer hijacking mechanisms on ecDNAs. **A.** Schematic models illustrating the identification of enhancer hijacking events on ecDNAs that involve multiple oncogenes from different chromosomal regions. **B.** Plotted are the calculated trans-enhancer contribution (x-axis) and the copy number estimated by SNP-array data (y-axis) for each HAPI gene in COLO320DM cells. **C.** HiChIP, ChIP-seq, and SNP-array-based copy number signal at the DNA segments of the ecDNA found in COLO320DM cells. **D.** Enhancer distribution of *MYC* and the additional oncogenes harbored in the ecDNA found in COLO320DM cells. Enhancers within 2mb of distance to the promoter of *MYC* or any other gene in the endogenous chromosomal locus will be considered as the gene's 'own' enhancers, otherwise will be considered as 'other' enhancers. **E.** Circos plot: layer 1=chromosome, 2=RNA-seq, 3=CNV, 4=enhancers (grey) and super-enhancers (black), 5= HAPI TSS, 6=ecDNA segments, center= E-P loops (black) and WGS-predicted translocations (red) in COLO320DM cells. **F-I.** Same as B-E but with regards to the ecDNAs in SNU16 cells.

Enhancer hijacking among multiple oncogenes is prevalent on ecDNAs and complex chromosomal amplicons.

We reasoned that enhancer hijacking, together with high copy numbers of the involved genes, may indicate a unique signature for chimeric ecDNAs or chromosomal complex amplicons that contain multiple DNA segments in our HAPI analysis results. Indeed, we found three additional cell lines NCIH2170, NCIH446, and MCF7 that have clusters of highly amplified HAPI genes hijacking enhancers from different chromosomes (Figure 5A-C). We analyzed their WGS data using AmpliconArchitect, an algorithm to reconstruct amplicons⁵², which showed extensive rearrangements among the amplified regions harboring the enhancer-hijacking genes (Figure S5A-C).

In the lung squamous cell carcinoma cell line NCIH2170, we identified a cluster of trans enhancer hijacking genes from chromosomes 8 and 17 (Figure 5A). AmpliconArchitect analysis of WGS data predicted an ecDNA containing most of these HAPI genes and their hijacked enhancers (Figure S6A-B). In particular, we found that *ERBB2* (chromosome 17) and its surrounding oncogenes *MIEN1* and *IKZF3* strongly interact with *MYC*'s enhancers (Figure 5D-E). *ERBB2* was known to be an amplified and overexpressed gene in this cell line^{53,54}. Our analysis showed that, in addition to the copy number amplification, hijacking *MYC* enhancers on the same ecDNA may also contribute to *ERBB2* and its surrounding oncogenes' overexpression.

Additionally, in the small-cell lung cancer cell line NCIH446, HAPI analysis identified seven genes including known oncogenes *MYC*, *NFIB*, and *MTDH* with trans enhancer hijacking from regions of chromosomes 8 and 9 (Figure 5F-G). WGS analysis showed extensive translocations among these gene loci (Figure S6C). A recent study reported that the *MYC* locus in NCIH446 resides on the chromosome based on DNA Fluorescent In Situ Hybridization (FISH) results⁵⁵, which together with our results suggest that chromosomal complex amplicons are also capable of causing multiple oncogenes to hijack each other's enhancers.

Lastly, we identified 35 HAPI genes with trans enhancer hijacking in the ER α -positive breast cancer cell line MCF7, 28 of which are clustered within genomic regions of chromosomes 17 and 20 (Figure S7A). These include known oncogenes *TBX2* and *BRIP1* from chromosome 17, and *ZNF217* from chromosome 20. Accordingly, ampliconArchitect analysis predicted an ecDNA harboring most of these HAPI genes and their hijacked enhancers (Figures S7B-C). These oncogenes are highly interactive with each other's enhancers, indicating extensive enhancer hijacking spanning the ecDNA segments (Figures S7D).

In the aforementioned five cell lines that harbor ecDNAs or chromosomal complex amplicons, we observed both "opportunistic" (COLO320DM and NCIH2170) and "mutualistic" (MCF7, SNU16 and NCIH446) enhancer hijacking phenomena among multiple oncogenes on the same amplicon, which are associated with overexpression of the associated oncogenes (Figure S8A). Using publicly available AmpliconArchitect results from WGS data of primary patient tumors included in the PCAWG project⁵⁶, we identified 1299 amplicons containing previously annotated oncogenes. We found that most of these amplicons, either in the extrachromosomal or chromosomal forms, harbor additional DNA segments originating from other chromosomal regions. In 37.6% of these complex amplicons, we found multiple oncogenes from separate DNA segments that are now on the same amplicon (Figure 5H). One amplicon is predicted to be a *MYC-ERBB2* chimeric ecDNA, similar to what we report in NCIH2170 cells (Figure S8B). These analyses suggest that many of these amplicons could enable extensive enhancer hijacking among their harbored oncogenes in patient tumors.

Figure 5




Figure 5: Enhancer hijacking is prevalent on complex amplicons. **A-C.** Plotted are the calculated trans-enhancer contribution (x-axis) and the copy number estimated by SNP-array data (y-axis) for each HAPI gene in MCF7, NCIH446, and NCIH2170 cells. **D.** HiChIP, ChIP-seq (derived from HiChIP reads), and copy number profiles at DNA segments of the *MYC* ecDNA in NCIH2170 cells. **E.** Enhancer distribution of *MYC* and the additional oncogenes harbored in the ecDNA found in NCIH2170 cells. **F.** HiChIP, ChIP-seq (derived from HiChIP reads), and copy number profiles at DNA segments of the *MYC* amplicon in NCIH446 cells. **G.** Enhancer distribution of *MYC* and the additional oncogenes harbored in the amplicon found in NCIH446 cells. **H.** Summary of AmpliconArchitect data from PCAWG tumor samples: most of oncogene amplicons contain additional trans or cis DNA segments. Most of these complex amplicons contain multiple oncogenes originating from different DNA segments.

Functional exploration of chimeric ecDNA-associated enhancer hijacking.

To validate the presence of chimeric ecDNAs that contain multiple oncogenes from different chromosomes, we performed DNA FISH in NCIH2170 cells using two probes targeting the *MYC* and *ERBB2* regions separately. DNA FISH on metaphase spreads showed the presence of ecDNAs containing both *MYC* and *ERBB2* across examined cells (Figure 6A). However, some of the ecDNAs contain only *MYC* or *ERBB2*, suggesting the intracellular heterogeneity of ecDNA compositions similar to what was reported previously in SNU16⁴⁶. DNA

FISH in interphase nuclei showed similar overlap between *MYC* and *ERBB2* signal across the examined cells (Figure S9A). We also observed the presence of ecDNA aggregates in some of the interphase nuclei, indicative of ecDNA hubs as previously reported in other cancer cell lines⁴⁶ (Figure S9B). These results demonstrate the presence of highly abundant *MYC-ERBB2* chimeric ecDNA in NCIH2170 cells.

The presence of chimeric *MYC* ecDNAs may provide novel therapeutic opportunities. For instance, although *MYC* as a transcription factor is difficult to target by small molecules, *ERBB2* is considered highly targetable. Indeed, NCIH2170 exhibits the strongest sensitivity to HER2 inhibitors lapatinib and neratinib among all the lung squamous cancer cell lines tested in the Cancer Therapeutics Response Portal (CTRP) CTD² project (Figure 6B).

We then sought to assess the regulatory function of enhancers on the *MYC-ERBB2* ecDNA. Due to the large number of potential *MYC* enhancers that are shared by these genes (Figure 5D), individually repressing these enhancers may not reflect their combinatorial activity. As an alternative strategy, we used CRISPRi to repress the *MYC* promoter and released all *MYC* enhancers from *MYC* to assess their effect on expression of *ERBB2* and its neighboring genes that also use these enhancers (illustrated in Figure 6C). HiChIP assays showed that CRISPRi resulted in an overall significant decrease in interactions between the *MYC* promoter and its enhancers, as expected (Figure 6D-E). In contrast, *ERBB2* gained interactions with these enhancers after CRISPRi of the *MYC* promoter (Figure 6E). RNA-seq showed that CRISPRi represses *MYC* expression and causes a significant increase in expression of *ERBB2* (2.7 folds) and its neighboring genes *MIEN1*, *PGAP3*, and *GRB7* (Figure 6F). For the remaining affected genes, we found enrichments of *MYC* up- and down-regulated gene sets, suggesting that they are secondary effects of *MYC* repression (Figure S10). All these results demonstrate that, on the chimeric *MYC-ERBB2* ecDNA in NCIH2170 cells, while *MYC* retains its interaction with its endogenous enhancers, *ERBB2* and its neighboring genes opportunistically hijack *MYC* enhancers on the same ecDNA for their transcriptional activation.

DISCUSSION

Enhancer hijacking caused by structural alterations is an oncogenic event in cancer; however, it remains difficult to detect due to the complexity of cancer genomes. Here, we presented a two-step strategy, namely HAPI, to robustly detect enhancer hijacking events based on: 1) oncogenes subject to enhancer hijacking should be highly regulated by enhancers, 2) the hijacked enhancers should contribute to a substantial proportion of an oncogene's enhancer activity. This assumption is supported by recent work using CRISPR to generate *de novo* enhancer translocations to the *MYC* locus, which showed that the combination of enhancer activity and contact from the translocated regions determines *MYC* activation⁵⁷. Although our analysis was based on H3K27ac HiChIP data, we expect it to be compatible with other types of high-resolution enhancer-promoter contact mapping assays such as PLAC-seq, Micro-C, and ChIA-PET⁵⁸⁻⁶⁰.

We first found hundreds of HAPI genes in each cell line whose promoters are highly interactive with enhancers. Previous work focused on neural cells found that genes that specify lineage development exhibit this pattern⁶¹. Our analysis in cancer cell lines found that oncogenes are also enriched in this category. We then prioritized HAPI genes that have a substantial amount of enhancer activity originating from other chromosomes or abnormally distant intra-chromosomal regions. This led to the identification of known and potentially novel enhancer-hijacking events regardless of the underlying structural variants such as balanced translocation, cryptic insertion, large deletion, as well as ecDNA formation. Although several of the identified oncogenes such as *MYC*, *ETV1*, and *CCND1* have been previously linked to enhancer hijacking, we identified their novel hijacked enhancers that are cancer type specific. The analysis also identified potentially novel enhancer-hijacking oncogenes such as *CRKL* and *ID4*. We have made the HAPI analysis tool publicly available (URL: <https://codeocean.com/capsule/2804329>) and anticipate its broader application in cancer driver discovery and mechanism investigation.

Figure 6




Figure 6: Functional exploration of the *MYC-ERBB2* chimeric ecDNA. A. Representative images of metaphase chromosome spreads showing highly amplified copies of *MYC* (red) and *ERBB2* (green) colocalizing outside of chromosomal DNA (blue, DAPI staining) in NCIH2170 cells. Scale bar, 5 μ m. Four enlarged regions of interest (ROI) were highlighted. Scale bar, 2 μ m. **B.** AUC values representing the sensitivity of lung squamous carcinoma cell lines to Neratinib and Lapatinib. **C.** Schematic illustration of the experimental design of the *MYC*-promoter CRISPRi assay. **D.** Virtual 4C signal (derived from HiChIP data) showing interactions with the *MYC* promoter at the chromosome 8 locus (now on ecDNA) in NCIH2170 cells (sgNT1, replicate 1). **E.** Virtual 4C signal between the promoter of *MYC* (upper) or *ERBB2* (lower) and five highlighted enhancer regions representing different levels of interaction intensity in NCIH2170 cells with (sg*MYC*-prom) and without (sgNT1) *MYC* promoter repression. SEM: standard error of the mean. N=2 biological replicates. **F.** The averaged virtual 4C signal between the top 50 *MYC*-interacting regions from the *MYC* locus (ranked by their interactions with the *MYC* promoter) and the promoter of *MYC* (left) or *ERBB2* (right). **G.** A volcano plot presenting RNA-seq results from NCIH2170 cells with and without *MYC* promoter repression. Two separate sgRNAs were used for each condition (sgNT1/sgNT2, sg*MYC*-prom#1/ sg*MYC*-prom#2). Highlighted are the genes on the *MYC-ERBB2* ecDNA that are significantly differentially expressed.

In addition to individual enhancer-hijacking events caused by simple DNA rearrangements, we identified nested enhancer-hijacking on complex amplicons, such as ecDNAs, that involve multiple oncogenes originating from different chromosomal regions. Our analysis of previously characterized as well as our newly identified ecDNAs shows that ecDNAs may contain multiple oncogenes from different chromosomes, which we refer to as chimeric ecDNAs. These structures were predicted by WGS analysis and validated by either optical imaging from previous work^{46,62} or dual-color DNA FISH in this study. We revealed two types of enhancer hijacking mechanisms associated with chimeric ecDNAs, as exemplified by *MYC* ecDNAs in this study. For the *MYC* ecDNAs found in COLO320DM and NCIH2170 cells, while *MYC* mainly uses its own enhancers, the additional oncogenes such as *CDX2* and *ERBB2* that are translocated to the *MYC* ecDNAs heavily use *MYC* enhancers for their activation, representing an “opportunistic” enhancer hijacking mechanism. For the *MYC* ecDNA found in SNU16 cells, *MYC* and the co-amplified *CD44* gene use each other’s enhancers in a more balanced manner, representing a “mutualistic” enhancer hijacking mechanism. These regulatory mechanisms became apparent through HAPI analysis of enhancer contribution (Figures 4D, 4H, 5E, 5G) and were validated by CRISPRi (Figure 6). These results provide important insights about a new layer of complexity for oncogene amplification and overexpression.

Chimeric ecDNAs may be prevalent in cancer. A recent work reported that 33.1% of ecDNAs found in Barrett’s oesophagus and esophageal adenocarcinomas contain multiple oncogenes on the same molecule based on WGS analysis⁶³. In addition to ecDNAs, chromosomal translocations often precede amplifications, also causing co-amplification two oncogenes from distinct chromosomal regions⁶⁴. Characterization of these chromosomal or extrachromosomal complex amplicons may reveal novel therapeutic strategies. As exemplified in this study, although *MYC* is a notoriously difficult drug target, *ERBB2* that is co-amplified with *MYC* is highly targetable.

Our finding of mutualistic or opportunistic enhancer hijacking mechanisms on different chimeric ecDNAs has important implications for the future of CRISPR-based therapeutics being developed to silence oncogenes. Targeting the shared enhancers on chimeric ecDNAs that are contributing to overexpression of multiple oncogenes is an appealing therapeutic strategy to repressed multiple oncogenes simultaneously. However, we also demonstrate that repressing the *MYC* promoter on a chimeric ecDNA released the shared enhancers from *MYC* and increased *ERBB2*’s opportunistic enhancer hijacking and expression. This could be a strategy to further sensitize the tumor to HER2 inhibitors, or it could be disastrous in increasing growth factor driven proliferation. These examples illustrate the importance of identifying and characterizing these complex regulatory mechanisms involving multiple oncogenes in order to develop effective CRISPR-based therapeutic strategies.

One limitation of our work is that we primarily used cell lines as our experimental models because they are relatively homogenous and easy to engineer. We used WGS data from primary human tumors in PCAWG to support our conclusions about the presence of complex rearrangements involving multiple oncogenes but the functional validation of enhancer hijacking in primary human tumors requires further development of 3D genomics assays and analysis methods that account for their intrinsic heterogeneity. In addition, we focused on trans-enhancer hijacking events that are caused by structural alterations. Many cis-enhancer hijacking events may

be caused by other types of genomic alterations such as point mutations and small indels as well as epigenetic alterations such as DNA methylation that are capable of disrupting TAD domains, which fall outside the scope of this manuscript. Future efforts integrating additional model systems and genomic/epigenomic analysis may address these limitations.

In summary, applying a two-step HAPI analysis, we identified and characterized enhancer-hijacking events that are caused by chromosomal and extrachromosomal structural alterations in cancer. Our findings reveal novel mechanisms underlying the activation of oncogenes that reside together on complex amplicons such as ecDNAs.

METHODS

Cell lines

Prostate cancer cell lines LNCaP, MDAPCA2B, 22Rv1, and VCaP, ER α -positive breast cancer cell lines ZR751, T47D, and MCF7, lymphoma cell lines REC1 and DOHH2, and lung squamous cell line NCIH2170 were obtained from the Cancer Cell Line Encyclopedia (CCLE)^{65,66}. The lymphoma cell line CUTLL1 was obtained from Sigma. VCaP, MCF7, and MDA-PCA-2B cells were grown in DMEM media supplemented with 10% FBS, and the rest of the cell lines were grown in RPMI media supplemented with 10% FBS. The identities of the cell lines were either verified by the CCLE project using SNP fingerprinting^{65,66} or short tandem repeat analysis through IDEXX. All the cell lines were tested negative for mycoplasma.

HiChIP and loop calling

HiChIP assays were performed for the following cell lines: LNCaP, T47D, CUTLL1, REC1, VCaP, MDA-PCA-2B, 22Rv1, ZR751, MCF7, DOHH2, and NCIH2170 as described in the published protocol⁶⁷ with minor modifications described previously⁶⁸. Cross-linked chromatin was digested with the MboI restriction enzyme, filled with dNTPs including biotin labeled dATP, ligated with T4 DNA ligase, and sonicated to obtain chromatin fragments averaging ~1 kb in length using Qsonica (Q800). To enrich for chromatin interactions at active regulatory elements, antibodies of H3K27ac (Abcam, ab4729, rabbit polyclonal, 7.5 μ g/HiChIP) were used for DNA fragment capture. Streptavidin magnetic beads were applied to pull down fully ligated DNA fragments and HiChIP libraries were prepared using Illumina Tagment DNA Enzyme and Buffer Kit. Sequencing was done with Illumina NextSeq. HiChIP data from the other cell lines included in the study was obtained from the NCBI Gene Expression Omnibus (GEO) (Table S1).

The paired-end HiChIP sequencing reads were aligned to human genome hg19 with the HiC-Pro pipeline⁶⁹. Hichipper was then used to call chromatin loops where DNA anchors were assigned, and the number of PETs connecting the anchors⁷⁰. Loop anchors were either called by hichipper based on enrichment of HiChIP sequencing reads or derived from broadpeaks called by MACS2 using publicly available H3K27ac ChIP-seq data in the corresponding cell lines, as indicated in Table S1. If multiple biological replicates of HiChIP data are available, the reads of replicates were merged prior to analysis. Chromatin loops were removed if their PETs <3 or anchors overlap with ENCODE blacklist regions⁷¹. HiChIP data was visualized at the resolution of 5kb using the R package gTrack³ (URL: <https://github.com/mskilab/gTrack>) or Circos⁷².

HAPI Analysis

We grouped the loops, called by hichipper, into ‘normal,’ ‘abnormal cis’, and ‘trans’ groups. Normal Chromatin interactions spanning more than 5 kb and less than 2 mb were considered normal loops. Intra-chromosomal interactions, whose anchors are separated by at least 2 mb and are not based within telomere regions (200 kb from each end of a chromosome) were considered abnormal long-range cis chromatin loops. Inter-chromosomal interactions whose anchors are not within telomere regions were treated as trans chromatin loops. The H3K27ac HiChIP anchors were then intersected with transcription start sites \pm 2.5 kb using bedtools⁷³ to identify promoters and enhancers. We consider a HiChIP loop that has a promoter in only one of its anchors as an enhancer-promoter loop. As promoters may act as enhancers or repressors for another gene⁷⁴⁻⁷⁶, we excluded promoter-promoter interactions for our analysis.

To identify highly interactive genes, all types of enhancer-promoter interactions (normal, abnormal cis, and trans) described above were combined. In the case of genes that have multiple promoters, the promoter with the most PETs stemming from it is used as the primary anchor for enhancer-promoter interactions. Then for every gene, two scores were calculated to account for the number and strength of interactions between a promoter and its enhancers. The first score, defined as an enhancer contact value, is the number of anchors (enhancers) that are looped to the promoter of a gene. The second score, defined as interaction intensity value, is the summation of the paired-end tags (PETs) that support the chromatin interactions. Genes are then ranked based on these scores individually and are presented in hockey stick plots. The inflection points of these plots, defined as the point where the line with a slope of ((max value-min value)/number of values) is tangent to the curve, are the cutoff

values to define genes with a significant enhancer contacts values or interaction intensity. Genes with both scores above their respective cutoffs are defined as HAPI genes.

To determine what types of enhancers are interacting with HAPI genes, the trans and long-range cis interaction data sets with enhancer contact values and interaction intensity calculated for each gene as described above are used. Then a percent enhancer contribution is calculated for each HAPI gene using the following formula for both trans and long-range cis interaction data:

$$\text{Enhancer Contribution} = \frac{\log_{10}(\text{cis OR trans PETs}) + \text{cis OR trans anchors}}{(\log_{10}(\text{local PETs}) + \text{local anchors}) + (\log_{10}(\text{cis PETs}) + \text{cis anchors}) + (\log_{10}(\text{trans PETs}) + \text{trans anchors})}$$

Using this formula, A gene with a score near zero is highly interactive with local enhancers. In contrast, genes with a higher trans enhancer contribution have a higher number of interacting enhancers and stronger interaction intensity coming from a different chromosome. Similarly, genes with a higher abnormal enhancer contribution interact with a higher number of enhancers and stronger interaction intensity coming from regions greater than 2 mb away on the same chromosome. We focus on the genes that have more than 25% of enhancer activity contributed in trans or cis.

The HAPI analysis tool is publicly available on Code Ocean (<https://codeocean.com/capsule/2804329>).

Copy number analysis

TCGA copy number segment data for all applicable cell lines were downloaded from the Broad Institute Portal (URL: https://data.broadinstitute.org/ccle_legacy_data/dna_copy_number/CCLE_copynumber_2013-12-03.seg.txt; DOI: <https://doi.org/10.1038/ng.3984>; downloaded in November, 2020).

Clustering analysis

An interaction score was calculated for all HAPI genes in each cell line by multiplying the \log_{10} of the interaction intensity by the enhancer contact value (interaction score = $\log_{10}(\text{interaction intensity}) * (\text{enhancer contact value})$) and normalized across all the cell lines. The clustering analysis was based on Spearman pairwise sample correlation. Heatmap was generated using the heatmap.2 function in the gplots R package.

Pathway analysis and oncogene enrichment analysis

Cell lines were grouped based on clustering analysis as described above and shared HAPI genes within each group were identified. GSEA analysis (MSigDB) was performed to identify the top KEGG canonical pathways⁷⁷⁻⁷⁹ and Gene Ontology biological processes and molecular functions^{80,81} enriched in the HAPI genes^{82,83}. The shared HAPI and non-HAPI genes in each group were also compared to a list of known oncogenes merged from three previously published oncogene data sets³⁴⁻³⁶. Fisher exact tests were used to calculate oncogene enrichment in the HAPI genes.

RT-qPCR

The Zymo Quick-RNA miniprep kit paired with on-column DNase I treatment was used to extract total RNA. To make cDNA for RT-qPCR, 1µg of RNA was used with the NEB LunaScript SuperMix kit. Real-time PCR was completed with NEB Luna Universal qPCR Master Mix on a Bio-Rad CFX96 qPCR instrument with technical replicates. The qPCR signal was first normalized to the internal reference gene *CTCF* and then the non-targeting sgRNA (sgNT1). RT-qPCR primers are listed in Table S4.

RNA-seq

CCLE RNA-seq data were downloaded from the DepMap portal (<https://depmap.org/portal/>)⁶⁵ (DOI: <https://doi.org/10.6084/m9.figshare.19700056.v2>; downloaded in May, 2022). Additional RNA-seq data for the CUTLL1 cell line was downloaded from GSE61999 and aligned to hg19 using Bowtie2⁸⁴ and gene expression was calculated using RSEM⁸⁵. The $\log_2(\text{TPM}+1)$ values of CUTLL1 were merged with the CCLE dataset for comparison.

For determining androgen dependence of *ETV1* expression in LNCaP and 22RV1, RNA-seq data for both cell lines grown in androgen-depleted media treated with DHT or vehicle were downloaded from GSE92574. Counts per million reads were used to determine the log₂ fold change in expression between control and treated cells. We generated RNA-seq data for the CRISPRi experiment in NCIH2170 cells and performed edgeR analysis⁸⁶ to identify differentially expressed genes (FDR<0.05; Fold change>1.5).

ChIP-seq

ChIP-seq was performed in LNCaP-dCas9-KRAB-MeCP2 cells treated with enhancer-targeting or non-targeting sgRNAs, as previously described⁶⁸. Five million cells were crosslinked with 1% formaldehyde (diluted in 1× phosphate-buffered saline (PBS)) and lysed with Lysis Buffer I (5 mM PIPES pH 8.0, 85 mM KCl, 0.5% NP40) and then Lysis Buffer II (1× PBS, 1% NP40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate) supplemented with protease inhibitors. Chromatin extract was sonicated with Bioruptor (20 min; pulse: 30 s on/30 s off; high amplitude) and immunoprecipitated with H3K27ac antibody (Abcam, ab4729, rabbit polyclonal, 4 µg/ChIP) premixed with Dynabeads A and G. ChIP-seq libraries were prepared using NEBNext DNA Ultra II library prep kit and sequenced by Illumina MiSeq.

Remaining ChIP-seq data used in the study were obtained from previously published datasets (Table S1). ChIP-seq reads and genomic input reads, if available, were aligned to the hg19 using Bowtie2⁸⁴. Samtools⁸⁷ was used to sort and index aligned reads followed by MACS2⁸⁸ to calculate the signal per million reads (SPMR) and to call significant peaks (q value < 0.05). Super-enhancers were called using H3K27ac ChIP-seq signal using the Homer pipeline⁸⁹ and then were compared to HiChIP loop anchors to determine which gene(s) they interact with utilizing bedtools⁷³.

CRISPR-mediated enhancer repression

To repress enhancers via CRISPR, we used a lentiviral dCas9-KRAB-MeCP2 vector that was previously generated²⁸. Cells were infected with the vector and selected with blasticidin (10 µg/ml) for >5 days to stably express dCas9-KRAB-MeCP2. sgRNAs were designed to target the peaks of DNase I hypersensitive regions and the trough of H3K27ac ChIP-seq profiles for either enhancer or promoter regions of interest. The promoter- or enhancer-targeting sgRNAs and non-targeting sgRNAs with no genome recognition sites were cloned into LentiGuide-Puro (Addgene: 52963). The cells stably expressing dCas9-KRAB-MeCP2 were infected with these vectors and then selected with puromycin (2 µg/ml) for at least 3 days before extracting RNA. All sgRNA sequences used are listed in Table S4.

WGS data processing and structural variant calling

WGS data for LNCaP, MCF7, ZR751, H446, H2170, COLO320DM, and SNU16 was downloaded from two published studies (Table S1). Raw FASTQ files were aligned to hg19 using BWA-MEM⁹⁰ and the aligned reads were sorted and indexed with Samtools⁸⁷. Structural variants and their breakpoints were called using GRIDSS^{91,92}. The output VCF files were converted to bedpe files and filtered by QUAL ≥ 1000, AS>0, and RAS>0 for translocation visualization using the BioConductor package StructuralVariantAnnotation⁹³.

PCAWG structural variants

PCAWG consensus call sets of structural variants in tumor samples were downloaded from the ICGC Data Portal (URL: https://dcc.icgc.org/releases/PCAWG/consensus_sv; DOI: <https://doi.org/10.1038/s41586-020-1969-6>; downloaded in January, 2023) and presented using Circos⁷².

For PCAWG complex amplicon analysis, we used the publicly available AmpliconArchitect results released from the AmpliconRepository (<https://ampliconrepository.org>; DOI: <https://doi.org/10.1038/s41467-018-08200-y>; downloaded in October, 2023). We used the “aggregated results” file in the “PCAWG – full” dataset released on August 29, 2023, which listed the DNA segments included in each amplicon. To identify DNA segments harboring oncogenes, we used a list of known oncogenes merged from three previously published oncogene data sets³⁴⁻³⁶.

ecDNA calling

To call ecDNAs in CCLE cell lines we employed the AmpliconSuite pipeline (<https://github.com/jluebeck/AmpliconSuite-pipeline>). Briefly, WGS data were aligned to hg19 using BWA⁹⁰ and amplified regions were called with cnvkit⁹⁴. Seed regions for AmpliconArchitect⁵² were identified using the default settings of the prepareAA script. AmpliconArchitect⁵² was used to identify ecDNAs. AmpliconClassifier⁶³ was used to determine if the amplicons represent ecDNAs and CycleViz (URL: <https://github.com/jluebeck/CycleViz>) was used to visualize the reconstructed ecDNA.

TCGA ATAC analysis

We downloaded the TCGA ATAC-seq data⁹⁵ from the NCI Genomic Data Commons data portal (URL: <https://gdc.cancer.gov/about-data/publications/ATACseq-AWG>; DOI: <https://doi.org/10.1126/science.aav1898>; downloaded in August, 2022), which contains log2-transformed normalized ATAC-seq insertion counts for each tested sample across the identified pan-cancer ATAC peaks. To compare chromatin openness of the hijacked enhancers across different cancer types, we first grouped hijacked enhancers that are within 2 kb distance to each other as an enhancer cluster, and then summed the log2 normalized ATAC-seq counts from ATAC peaks found in each enhancer cluster to determine its overall chromatin openness for each sample included in the tested cancer types.

Dual-color DNA FISH

Metaphase arrest of H2170 cells was performed by incubation with KaryoMAX (Gibco) at 0.1 ug mL⁻¹ overnight. Single cell suspension of the metaphase arrested cells was resuspended in 1xPBS followed by incubation with 75 mM KCL for 15-30 min. The cells were fixed with 3:1 methanol to glacial acetic acid overnight and then washed three times with the fixative before being dropped on a coverslip. The coverslip was dried for 5 min at 60°C before being immersed in 2xSSC in preparation for DNA FISH.

Coverslips with fixed cells in metaphase were washed twice for 5 min with 2xSSC. The coverslips were then washed with 50% formamide/1xSSC for 4 min and dehydrated through a series of ethanol incubations (70%, 85%, and 100%) for 2 min each. Next, the coverslips were placed on slides containing a 1:1 ratio of ERBB2 to MYC FISH probes diluted in the manufacturer's hybridization buffer (Empire Genomics). The coverslips were sealed with rubber cement and denatured in a heated incubator at 82°C for 1 min, followed by incubation in a humidified chamber at 37°C overnight. The coverslip was washed once with 0.4xSSC/0.3% Igepal at 73°C and twice with 2xSSC/0.1% Igepal each for 2min. A final two washes with 2xSSC were performed before mounting the coverslip using Prolong Antifade Mountants with DAPI (Thermo Fisher).

For interphase DNA FISH, H2170 cells were seeded on collagen-coated coverslips and fixed with 4% PFA in 1xPBS for 10 min, followed by quenching for 10 min with 0.1 M Glycine in 1x PBS. The cell membrane was then permeabilized for 10 min with 0.5% Triton-X 100. An additional three 5 min rinses with 1xPBS preceded RNase A treatment at 0.1 ug mL⁻¹ for 1 hour at 37°C, followed by three more rinses with 1xPBS before a 10 min incubation with 0.7% Triton X-100 in 0.1 M HCl on ice. After three rinses with PBS, the coverslips were incubated for 30 min in 2x SSC with 50% formamide. During the incubation, the hybridization buffer containing 2x SSC, 1 µl each of MYC and ERBB2 FISH probes (Empire Genomics), 50% (v/v) formamide, 2% dextran sulfate, and 0.2 µl 10 mg mL⁻¹ salmon sperm DNA was prepared and 10 µl was placed on the slide. The coverslips were then placed on the hybridization buffer on the slide and sealed with rubber cement. Denaturation was performed in a heated incubator at 78°C for 4 min followed by incubation overnight at 37°C in a humidified chamber. The coverslips were then washed three times with 50% formamide in 2xSSC for 5 min each at 37°C. An additional three washes with 2xSSC at 37°C were performed before mounting with Prolong Antifade Mountants with DAPI (Thermo Fisher).

All DNA FISH samples were imaged using a Nikon Eclipse Ti-2 microscope coupled with a CSU-W1 spinning disk confocal scanner unit (Yokogawa). Specifically, the fluorescent cell samples were excited using three laser lines: 405 nm, 488 nm, and 561 nm. The fluorescence signals were captured and detected using a Plan Apo 60x objective (Nikon, NA 1.40) and a high-speed Kinetix sCMOS camera (Photometrics), respectively. This

microscope utilizes the Nikon Perfect Focus System, an interferometry-based focus lock that allows the capture of multipoint images without loss of focus. All imaging data were examined and quantified using Fiji and Cell Profiler.

Virtual 4C Analysis

For HiChIP data from NCIH2170 cells with and without CRISPRi-mediated *MYC* promoter repression, we presented and compared their virtual 4C signal anchored at *MYC* or *ERBB2* promoters. Briefly, we first identified all valid read pairs (HiC-Pro output) that have one end mapped to a 2kb window centered at *MYC* or *ERBB2* TSS. We then used the other end of the read pairs to generate a bedgraph file at a 10bp resolution. The bedgraph signal was then scaled based on the total number of PETs identified in each condition. As most of enhancers used by *MYC* and *ERBB2* come from the chromosome 8 locus surrounding *MYC*. For presentation and comparison, we presented Virtual 4C signal at five regions from the *MYC* locus that are enriched with strong enhancer activity as well as the averaged Virtual 4C signal for the top 50 HiChIP signal-derived narrow peaks at the *MYC* locus that are ranked based on their interactions with the *MYC* promoter.

Data Availability

The ChIP-seq, HiChIP, and RNA-seq data generated in this study have been deposited to GEO under the series GSE228247. A secure token (wzmzwmeovzohqtb) has been created to review the deposited data.

Code Availability

HAPI analysis is available for public use with test examples as a module in Code Ocean at <https://codeocean.com/capsule/2804329>

Acknowledgments

We thank Matthew Meyerson, John Pulice, and Dean Tantin for insightful discussions.

The support and resources from the Center for High Performance Computing at the University of Utah are gratefully acknowledged.

Funding for this work was provided by R00CA215244 from the National Cancer Institute (XZ), 132596-RSG-18-197-01-DMC from the American Cancer Society (KEV), Huntsman Cancer Institute's National Cancer Institute Cancer Center Support Grant (P30CA042014) and the Huntsman Cancer Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests

The authors declare no competing interest regarding this work.

Supplemental Data

Tables S1-4

Figures S1-9

REFERENCE

- 1 Zhang, X. & Meyerson, M. Illuminating the noncoding genome in cancer. *Nat Cancer* **1**, 864-872 (2020). <https://doi.org/10.1038/s43018-020-00114-3>
- 2 Li, Y. *et al.* Patterns of somatic structural variation in human cancer genomes. *Nature* **578**, 112-121 (2020). <https://doi.org/10.1038/s41586-019-1913-9>
- 3 Hadi, K. *et al.* Distinct Classes of Complex Structural Variation Uncovered across Thousands of Cancer Genome Graphs. *Cell* **183**, 197-210 e132 (2020). <https://doi.org/10.1016/j.cell.2020.08.006>
- 4 Garraway, L. A. & Lander, E. S. Lessons from the cancer genome. *Cell* **153**, 17-37 (2013). <https://doi.org/10.1016/j.cell.2013.03.002>
- 5 Stratton, M. R., Campbell, P. J. & Futreal, P. A. The cancer genome. *Nature* **458**, 719-724 (2009). <https://doi.org/10.1038/nature07943>
- 6 Soda, M. *et al.* Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. *Nature* **448**, 561-566 (2007). <https://doi.org/10.1038/nature05945>
- 7 Bartram, C. R. *et al.* Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. *Nature* **306**, 277-280 (1983). <https://doi.org/10.1038/306277a0>
- 8 Rheinbay, E. *et al.* Analyses of non-coding somatic drivers in 2,658 cancer whole genomes. *Nature* **578**, 102-111 (2020). <https://doi.org/10.1038/s41586-020-1965-x>
- 9 Groschel, S. *et al.* A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia. *Cell* **157**, 369-381 (2014). <https://doi.org/10.1016/j.cell.2014.02.019>
- 10 Ryan, R. J. *et al.* Detection of Enhancer-Associated Rearrangements Reveals Mechanisms of Oncogene Dysregulation in B-cell Lymphoma. *Cancer Discov* **5**, 1058-1071 (2015). <https://doi.org/10.1158/2159-8290.CD-15-0370>
- 11 Northcott, P. A. *et al.* Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. *Nature* **511**, 428-434 (2014). <https://doi.org/10.1038/nature13379>
- 12 Tsujimoto, Y. *et al.* Clustering of breakpoints on chromosome 11 in human B-cell neoplasms with the t(11;14) chromosome translocation. *Nature* **315**, 340-343 (1985). <https://doi.org/10.1038/315340a0>
- 13 Battey, J. *et al.* The human c-myc oncogene: structural consequences of translocation into the IgH locus in Burkitt lymphoma. *Cell* **34**, 779-787 (1983). [https://doi.org/10.1016/0092-8674\(83\)90534-2](https://doi.org/10.1016/0092-8674(83)90534-2)
- 14 Dubois, F. P. B. *et al.* Structural variants shape driver combinations and outcomes in pediatric high-grade glioma. *Nat Cancer* **3**, 994-1011 (2022). <https://doi.org/10.1038/s43018-022-00403-z>
- 15 Helmsauer, K. *et al.* Enhancer hijacking determines extrachromosomal circular MYCN amplicon architecture in neuroblastoma. *Nat Commun* **11**, 5823 (2020). <https://doi.org/10.1038/s41467-020-19452-y>
- 16 Bandopadhyay, P. *et al.* MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. *Nat Genet* **48**, 273-282 (2016). <https://doi.org/10.1038/ng.3500>

- 17 Drier, Y. *et al.* An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma. *Nat Genet* **48**, 265-272 (2016). <https://doi.org/10.1038/ng.3502>
- 18 Weischenfeldt, J. *et al.* Pan-cancer analysis of somatic copy-number alterations implicates IRS4 and IGF2 in enhancer hijacking. *Nat Genet* **49**, 65-74 (2017). <https://doi.org/10.1038/ng.3722>
- 19 Giongo, A. *et al.* PANGEA: pipeline for analysis of next generation amplicons. *The ISME Journal* **4**, 852-861 (2010). <https://doi.org/10.1038/ismej.2010.16>
- 20 Wang, X. *et al.* Genome-wide detection of enhancer-hijacking events from chromatin interaction data in rearranged genomes. *Nat Methods* **18**, 661-668 (2021). <https://doi.org/10.1038/s41592-021-01164-w>
- 21 Shoshani, O. *et al.* Chromothripsis drives the evolution of gene amplification in cancer. *Nature* **591**, 137-141 (2021). <https://doi.org/10.1038/s41586-020-03064-z>
- 22 Hung, K. L., Mischel, P. S. & Chang, H. Y. Gene regulation on extrachromosomal DNA. *Nat Struct Mol Biol* **29**, 736-744 (2022). <https://doi.org/10.1038/s41594-022-00806-7>
- 23 Wu, S., Bafna, V., Chang, H. Y. & Mischel, P. S. Extrachromosomal DNA: An Emerging Hallmark in Human Cancer. *Annu Rev Pathol* **17**, 367-386 (2022). <https://doi.org/10.1146/annurev-pathmechdis-051821-114223>
- 24 Yi, E., Chamorro Gonzalez, R., Henssen, A. G. & Verhaak, R. G. W. Extrachromosomal DNA amplifications in cancer. *Nat Rev Genet* **23**, 760-771 (2022). <https://doi.org/10.1038/s41576-022-00521-5>
- 25 Whyte, W. A. *et al.* Master transcription factors and mediator establish super-enhancers at key cell identity genes. *Cell* **153**, 307-319 (2013). <https://doi.org/10.1016/j.cell.2013.03.035>
- 26 Hnisz, D. *et al.* Super-enhancers in the control of cell identity and disease. *Cell* **155**, 934-947 (2013). <https://doi.org/10.1016/j.cell.2013.09.053>
- 27 Loven, J. *et al.* Selective inhibition of tumor oncogenes by disruption of super-enhancers. *Cell* **153**, 320-334 (2013). <https://doi.org/10.1016/j.cell.2013.03.036>
- 28 Liu, Y. *et al.* A predominant enhancer co-amplified with the SOX2 oncogene is necessary and sufficient for its expression in squamous cancer. *Nat Commun* **12**, 7139 (2021). <https://doi.org/10.1038/s41467-021-27055-4>
- 29 Zhang, X. *et al.* Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers. *Nat Genet* **48**, 176-182 (2016). <https://doi.org/10.1038/ng.3470>
- 30 Zhang, X. *et al.* Somatic Superenhancer Duplications and Hotspot Mutations Lead to Oncogenic Activation of the KLF5 Transcription Factor. *Cancer Discov* **8**, 108-125 (2018). <https://doi.org/10.1158/2159-8290.CD-17-0532>
- 31 Takeda, D. Y. *et al.* A Somatic Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer. *Cell* **174**, 422-432 e413 (2018). <https://doi.org/10.1016/j.cell.2018.05.037>
- 32 Viswanathan, S. R. *et al.* Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing. *Cell* **174**, 433-447 e419 (2018). <https://doi.org/10.1016/j.cell.2018.05.036>

- 33 Morton, A. R. *et al.* Functional Enhancers Shape Extrachromosomal Oncogene Amplifications. *Cell* **179**, 1330-1341 e1313 (2019). <https://doi.org/10.1016/j.cell.2019.10.039>
- 34 Chakravarty, D. *et al.* OncoKB: A Precision Oncology Knowledge Base. *JCO Precis Oncol* **2017**, 1-16 (2017). <https://doi.org/10.1200/PO.17.00011>
- 35 Liu, Y., Sun, J. & Zhao, M. ONGene: A literature-based database for human oncogenes. *J Genet Genomics* **44**, 119-121 (2017). <https://doi.org/10.1016/j.jgg.2016.12.004>
- 36 Sondka, Z. *et al.* The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers. *Nat Rev Cancer* **18**, 696-705 (2018). <https://doi.org/10.1038/s41568-018-0060-1>
- 37 Dekker, J. & Heard, E. Structural and functional diversity of Topologically Associating Domains. *FEBS Lett* **589**, 2877-2884 (2015). <https://doi.org/10.1016/j.febslet.2015.08.044>
- 38 Flavahan, W. A. *et al.* Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs. *Nature* **575**, 229-233 (2019). <https://doi.org/10.1038/s41586-019-1668-3>
- 39 Flavahan, W. A. *et al.* Insulator dysfunction and oncogene activation in IDH mutant gliomas. *Nature* **529**, 110-114 (2016). <https://doi.org/10.1038/nature16490>
- 40 Meyers, R. M. *et al.* Computational correction of copy number effect improves specificity of CRISPR–Cas9 essentiality screens in cancer cells. *Nature Genetics* **49**, 1779-1784 (2017). <https://doi.org/10.1038/ng.3984>
- 41 Dixon, J. R. *et al.* Integrative detection and analysis of structural variation in cancer genomes. *Nat Genet* **50**, 1388-1398 (2018). <https://doi.org/10.1038/s41588-018-0195-8>
- 42 Parolia, A. *et al.* Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer. *Nature* **571**, 413-418 (2019). <https://doi.org/10.1038/s41586-019-1347-4>
- 43 Cai, C. *et al.* ETV1 is a novel androgen receptor-regulated gene that mediates prostate cancer cell invasion. *Mol Endocrinol* **21**, 1835-1846 (2007). <https://doi.org/10.1210/me.2006-0480>
- 44 Ortiz, A. B. *et al.* Prognostic significance of cyclin D1 protein expression and gene amplification in invasive breast carcinoma. *PLoS One* **12**, e0188068 (2017). <https://doi.org/10.1371/journal.pone.0188068>
- 45 Wu, S. *et al.* Circular ecDNA promotes accessible chromatin and high oncogene expression. *Nature* **575**, 699-703 (2019). <https://doi.org/10.1038/s41586-019-1763-5>
- 46 Hung, K. L. *et al.* ecDNA hubs drive cooperative intermolecular oncogene expression. *Nature* **600**, 731-736 (2021). <https://doi.org/10.1038/s41586-021-04116-8>
- 47 Salari, K. *et al.* CDX2 is an amplified lineage-survival oncogene in colorectal cancer. *Proc Natl Acad Sci U S A* **109**, E3196-3205 (2012). <https://doi.org/10.1073/pnas.1206004109>
- 48 Werling, R. W., Yaziji, H., Bacchi, C. E. & Gown, A. M. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. *Am J Surg Pathol* **27**, 303-310 (2003). <https://doi.org/10.1097/00000478-200303000-00003>
- 49 Hung, K. L. *et al.* Targeted profiling of human extrachromosomal DNA by CRISPR-CATCH. *Nat Genet* **54**, 1746-1754 (2022). <https://doi.org/10.1038/s41588-022-01190-0>

- 50 Hong, S. H. *et al.* APIP, an ERBB3-binding partner, stimulates erbB2-3 heterodimer formation to promote tumorigenesis. *Oncotarget* **7**, 21601-21617 (2016). <https://doi.org/10.18632/oncotarget.7802>
- 51 Hou, W., Kong, L., Hou, Z. & Ji, H. CD44 is a prognostic biomarker and correlated with immune infiltrates in gastric cancer. *BMC Med Genomics* **15**, 225 (2022). <https://doi.org/10.1186/s12920-022-01383-w>
- 52 Deshpande, V. *et al.* Exploring the landscape of focal amplifications in cancer using AmpliconArchitect. *Nat Commun* **10**, 392 (2019). <https://doi.org/10.1038/s41467-018-08200-y>
- 53 Estrada-Bernal, A. *et al.* Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes. *Clin Cancer Res* **27**, 1463-1475 (2021). <https://doi.org/10.1158/1078-0432.CCR-20-3555>
- 54 Ise, N., Omi, K., Nambara, D., Higashiyama, S. & Goishi, K. Overexpressed HER2 in NSCLC is a Possible Therapeutic Target of EGFR Inhibitors. *Anticancer Res* **31**, 4155-4161 (2011).
- 55 Pongor, L. S. *et al.* Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and Is Associated with Worse Outcomes. *Cancer Discov* **13**, 928-949 (2023). <https://doi.org/10.1158/2159-8290.CD-22-0796>
- 56 Aaltonen, L. A. *et al.* Pan-cancer analysis of whole genomes. *Nature* **578**, 82-93 (2020). <https://doi.org/10.1038/s41586-020-1969-6>
- 57 Xu, Z. *et al.* Structural variants drive context-dependent oncogene activation in cancer. *Nature* **612**, 564-572 (2022). <https://doi.org/10.1038/s41586-022-05504-4>
- 58 Hsieh, T. H. *et al.* Mapping Nucleosome Resolution Chromosome Folding in Yeast by Micro-C. *Cell* **162**, 108-119 (2015). <https://doi.org/10.1016/j.cell.2015.05.048>
- 59 Li, G. *et al.* Chromatin Interaction Analysis with Paired-End Tag (ChIA-PET) sequencing technology and application. *BMC Genomics* **15 Suppl 12**, S11 (2014). <https://doi.org/10.1186/1471-2164-15-S12-S11>
- 60 Fang, R. *et al.* Mapping of long-range chromatin interactions by proximity ligation-assisted ChIP-seq. *Cell Res* **26**, 1345-1348 (2016). <https://doi.org/10.1038/cr.2016.137>
- 61 Song, M. *et al.* Cell-type-specific 3D epigenomes in the developing human cortex. *Nature* **587**, 644-649 (2020). <https://doi.org/10.1038/s41586-020-2825-4>
- 62 Li, Y., Zhou, S., Schwartz, D. C. & Ma, J. Allele-Specific Quantification of Structural Variations in Cancer Genomes. *Cell Syst* **3**, 21-34 (2016). <https://doi.org/10.1016/j.cels.2016.05.007>
- 63 Luebeck, J. *et al.* Extrachromosomal DNA in the cancerous transformation of Barrett's esophagus. *bioRxiv*, 2022.2007.2025.501144 (2022). <https://doi.org/10.1101/2022.07.25.501144>
- 64 Lee, J. J. *et al.* ER α -associated translocations underlie oncogene amplifications in breast cancer. *Nature* **618**, 1024-1032 (2023). <https://doi.org/10.1038/s41586-023-06057-w>
- 65 Ghandi, M. *et al.* Next-generation characterization of the Cancer Cell Line Encyclopedia. *Nature* **569**, 503-508 (2019). <https://doi.org/10.1038/s41586-019-1186-3>
- 66 Barretina, J. *et al.* The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. *Nature* **483**, 603-607 (2012). <https://doi.org/10.1038/nature11003>

- 67 Mumbach, M. R. *et al.* HiChIP: efficient and sensitive analysis of protein-directed genome architecture. *Nat Methods* **13**, 919-922 (2016). <https://doi.org/10.1038/nmeth.3999>
- 68 Liu, Y. *et al.* Chromatin Looping Shapes KLF5-Dependent Transcriptional Programs in Human Epithelial Cancers. *Cancer Res* **80**, 5464-5477 (2020). <https://doi.org/10.1158/0008-5472.CAN-20-1287>
- 69 Servant, N. *et al.* HiC-Pro: an optimized and flexible pipeline for Hi-C data processing. *Genome Biol* **16**, 259 (2015). <https://doi.org/10.1186/s13059-015-0831-x>
- 70 Lareau, C. A. & Aryee, M. J. hichipper: a preprocessing pipeline for calling DNA loops from HiChIP data. *Nat Methods* **15**, 155-156 (2018). <https://doi.org/10.1038/nmeth.4583>
- 71 Amemiya, H. M., Kundaje, A. & Boyle, A. P. The ENCODE Blacklist: Identification of Problematic Regions of the Genome. *Sci Rep* **9**, 9354 (2019). <https://doi.org/10.1038/s41598-019-45839-z>
- 72 Krzywinski, M. *et al.* Circos: an information aesthetic for comparative genomics. *Genome Res* **19**, 1639-1645 (2009). <https://doi.org/10.1101/gr.092759.109>
- 73 Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing genomic features. *Bioinformatics* **26**, 841-842 (2010). <https://doi.org/10.1093/bioinformatics/btq033>
- 74 Oudelaar, A. M. *et al.* A revised model for promoter competition based on multi-way chromatin interactions at the alpha-globin locus. *Nat Commun* **10**, 5412 (2019). <https://doi.org/10.1038/s41467-019-13404-x>
- 75 Cho, S. W. *et al.* Promoter of lncRNA Gene PVT1 Is a Tumor-Suppressor DNA Boundary Element. *Cell* **173**, 1398-1412 e1322 (2018). <https://doi.org/10.1016/j.cell.2018.03.068>
- 76 Wijgerde, M., Grosveld, F. & Fraser, P. Transcription complex stability and chromatin dynamics in vivo. *Nature* **377**, 209-213 (1995). <https://doi.org/10.1038/377209a0>
- 77 Kanehisa, M. Toward understanding the origin and evolution of cellular organisms. *Protein Sci* **28**, 1947-1951 (2019). <https://doi.org/10.1002/pro.3715>
- 78 Kanehisa, M., Furumichi, M., Sato, Y., Kawashima, M. & Ishiguro-Watanabe, M. KEGG for taxonomy-based analysis of pathways and genomes. *Nucleic Acids Res* **51**, D587-D592 (2023). <https://doi.org/10.1093/nar/gkac963>
- 79 Kanehisa, M. & Goto, S. KEGG: kyoto encyclopedia of genes and genomes. *Nucleic Acids Res* **28**, 27-30 (2000). <https://doi.org/10.1093/nar/28.1.27>
- 80 Ashburner, M. *et al.* Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. *Nat Genet* **25**, 25-29 (2000). <https://doi.org/10.1038/75556>
- 81 Gene Ontology, C. The Gene Ontology resource: enriching a GOld mine. *Nucleic Acids Res* **49**, D325-D334 (2021). <https://doi.org/10.1093/nar/gkaa1113>
- 82 Liberzon, A. *et al.* Molecular signatures database (MSigDB) 3.0. *Bioinformatics* **27**, 1739-1740 (2011). <https://doi.org/10.1093/bioinformatics/btr260>
- 83 Subramanian, A. *et al.* Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A* **102**, 15545-15550 (2005). <https://doi.org/10.1073/pnas.0506580102>

- 84 Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. *Nat Methods* **9**, 357-359 (2012). <https://doi.org/10.1038/nmeth.1923>
- 85 Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. *BMC Bioinformatics* **12**, 323 (2011). <https://doi.org/10.1186/1471-2105-12-323>
- 86 Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics* **26**, 139-140 (2009). <https://doi.org/10.1093/bioinformatics/btp616>
- 87 Li, H. *et al.* The Sequence Alignment/Map format and SAMtools. *Bioinformatics* **25**, 2078-2079 (2009). <https://doi.org/10.1093/bioinformatics/btp352>
- 88 Zhang, Y. *et al.* Model-based analysis of ChIP-Seq (MACS). *Genome Biol* **9**, R137 (2008). <https://doi.org/10.1186/gb-2008-9-9-r137>
- 89 Heinz, S. *et al.* Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. *Mol Cell* **38**, 576-589 (2010). <https://doi.org/10.1016/j.molcel.2010.05.004>
- 90 Li, H. & Durbin, R. Fast and accurate long-read alignment with Burrows-Wheeler transform. *Bioinformatics* **26**, 589-595 (2010). <https://doi.org/10.1093/bioinformatics/btp698>
- 91 Cameron, D. L. *et al.* GRIDSS2: comprehensive characterisation of somatic structural variation using single breakend variants and structural variant phasing. *Genome Biol* **22**, 202 (2021). <https://doi.org/10.1186/s13059-021-02423-x>
- 92 Cameron, D. L. *et al.* GRIDSS: sensitive and specific genomic rearrangement detection using positional de Bruijn graph assembly. *Genome Res* **27**, 2050-2060 (2017). <https://doi.org/10.1101/gr.222109.117>
- 93 StructuralVariantAnnotation: Variant annotations for structural variants (2019).
- 94 Talevich, E., Shain, A. H., Botton, T. & Bastian, B. C. CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing. *PLoS Comput Biol* **12**, e1004873 (2016). <https://doi.org/10.1371/journal.pcbi.1004873>
- 95 Corces, M. R. *et al.* The chromatin accessibility landscape of primary human cancers. *Science* **362**, eaav1898 (2018). <https://doi.org/10.1126/science.aav1898>